Is Herantis Pharma Oyj (HRPMF) a Buy, Sell, or Hold?
OTC : HRPMF
Herantis Pharma Oyj
$3.51 USD
$0 (0.0%)
- Volume
- 1.1K
- Average Volume
- 0
- Market Capitalization
- $59.47M
- P/E Ratio
- -5.85
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $3.51
- Year Low
- $3.51
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.93
Company Overview
OTC
Antti Vuolanto D.Sc. (Tech)
Biotechnology
Healthcare
HRPMF
10
FI
USD
Liquidity Metrics
-2.04
2.93
2.93
0.82
0.00
Sales & Valuation
-$
0.00
-22.57
-6.87
-0.25
Profitability
-$0.24
-$4.94M
0.00%
0.00%
-21354.84%
-248.13%
P/E Metrics
-5.85
0.47
0.47
Analyst Price Target & Rating
0/5
0 Analysts
%
Financial Health Scores
-43.21
2/9
$1.94M
$2.57M
$2.81M
-$9.06M
Key Metrics (TTM)
$45.37M
0.00
-7.09
2.93
-21354.84%
-363.20%
-17.07%
-14.28%
0 days
Company Executives
| Name | Title |
|---|---|
| Antti Vuolanto | Chief Executive Officer & Chief Operating Officer |
| Sigrid Booms | Head of Regulatory Affairs & Compliance |
| Tone Kvale | Chief Financial Officer |
| Charlotte Videbaek | Clinical Consultant |
| Henri J. Huttunen | Chief Scientific Officer |
| Jani Koskinen | Head of CMC |
| Jutta Poutanen | Head of Quality |
| Outi Lahdenperä | Chief Medical Ofcer |
Poll Results
No votes yet today — be the first to share your view!
About Herantis Pharma Oyj (OTC:HRPMF) Stock
Herantis Pharma Oyj, a biotechnology enterprise, specializes in creating disease-modifying therapies for Parkinson's disease (PD) that harness Cerebral Dopamine Neurotrophic Factor (CDNF). Central to its developmental efforts is HER-096, a sophisticated, compact, synthetic chemical peptidomimetic originating from the active parent molecule. This preclinical xCDNF candidate is currently being investigated for its therapeutic promise in PD and other neurodegenerative conditions. Additionally, the firm is advancing recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF), a biological protein that is presently undergoing Phase I clinical evaluation in individuals afflicted with Parkinson's. Founded in 2008, Herantis Pharma Oyj maintains its corporate headquarters in Espoo, Finland. ...
Frequently Asked Questions
-
What is the current Herantis Pharma Oyj (HRPMF) stock price?
-
Herantis Pharma Oyj(OTC:HRPMF) stock price is $3.51 in the last trading session. During the trading session, HRPMF stock reached the peak price of $3.51 while $3.51 was the lowest point it dropped to. The percentage change in HRPMF stock occurred in the recent session was 0.0% while the dollar amount for the price change in HRPMF stock was $0.
-
HRPMF's industry and sector of operation?
-
The OTC listed HRPMF is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of HRPMF?
-
Antti Vuolanto | Chief Executive Officer & Chief Operating Officer
Sigrid Booms | Head of Regulatory Affairs & Compliance
Tone Kvale | Chief Financial Officer
Charlotte Videbaek | Clinical Consultant
Henri J. Huttunen | Chief Scientific Officer -
How many employees does HRPMF have?
-
Number of HRPMF employees currently stands at 10. HRPMF operates from Bertel Jungin Aukio 1, Espoo, None 02600, FI.
-
Link for HRPMF official website?
-
Official Website of HRPMF is: https://www.herantis.com
-
How do I contact HRPMF?
-
HRPMF could be contacted at phone #358 9222 1195 and can also be accessed through its website. HRPMF operates from Bertel Jungin Aukio 1, Espoo, None 02600, FI.
-
How many shares of HRPMF are traded daily?
-
The average number of HRPMF shares traded daily for last 3 months was 0.
-
What is the market cap of HRPMF currently?
-
The market value of HRPMF currently stands at $59.47M with its latest stock price at $3.51